Rebecca Kristeleit

Rebecca Kristeleit, MBBS, PhD, FRCP is Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust and Honorary Senior Lecturer at King's College London, where she leads a gynecologic oncology phase I/II drug development program. Previously based at the UCL Cancer Institute, she was a key investigator in the ARIEL2 study — the phase II rucaparib trial that established a three-segment model predicting rucaparib efficacy based on BRCA mutation and LOH-high genomic scar status, providing one of the most clinically influential biomarker analyses in ovarian cancer PARP inhibitor development. Dr. Kristeleit has been a principal investigator on numerous phase I/II trials of novel agents in gynecologic malignancies, including the first-in-human studies of several oral PARP inhibitors and cell cycle-targeting agents. Her translational research program focuses on mechanisms of PARP inhibitor resistance, the biology of platinum-resistant ovarian cancer, and the development of immune and targeted combination strategies to restore sensitivity. She is an active contributor to GCIG, NCRI, and ESGO trial networks and has authored over 100 peer-reviewed publications in ovarian and endometrial cancer. She is a respected educator and mentor in gynecologic oncology clinical trial medicine in the UK.